Previous studies demonstrated that CD137 stimulation of NK cells enhances mAb-mediated ADCC functions and works in synergy with anti-CD20, anti-HER2, and anti-EGFR mAbs in xenotransplant murine models of lymphoma, breast, colon, and head and neck cancer [16–18]. This evidence concerns the gene TNFRSF9 and head and neck cancer.